Keudell Morrison Wealth Management Invests $596,000 in Sanofi $SNY

Posted by Brian Himes on May 22nd, 2026

Keudell Morrison Wealth Management purchased a new position in shares of Sanofi (NASDAQ:SNY – Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 12,308 shares of the company’s stock, valued at approximately $596,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Flagship Harbor Advisors LLC purchased a new position in Sanofi during the 4th quarter worth $25,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Sanofi during the third quarter worth about $29,000. Palisade Asset Management LLC acquired a new position in shares of Sanofi during the third quarter worth about $30,000. Larson Financial Group LLC raised its holdings in Sanofi by 48.9% during the fourth quarter. Larson Financial Group LLC now owns 810 shares of the company’s stock worth $39,000 after purchasing an additional 266 shares in the last quarter. Finally, Sittner & Nelson LLC acquired a new stake in Sanofi in the third quarter valued at about $47,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Performance

SNY opened at $44.92 on Friday. Sanofi has a 1-year low of $42.33 and a 1-year high of $53.03. The stock has a market cap of $109.56 billion, a P/E ratio of 12.55, a P/E/G ratio of 1.10 and a beta of 0.35. The stock’s 50 day simple moving average is $45.58 and its 200 day simple moving average is $47.25. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be given a $2.4225 dividend. This is an increase from Sanofi’s previous annual dividend of $2.04. This represents a dividend yield of 559.0%. The ex-dividend date is Monday, May 4th. Sanofi’s dividend payout ratio (DPR) is 49.16%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Wall Street Zen lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a report on Monday, April 20th. Citigroup restated a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Argus upgraded Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat, Sanofi has a consensus rating of “Hold” and an average price target of $51.00.

View Our Latest Report on SNY

Sanofi Profile

(Free Report)

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.